Genmab | GEN

Stock Price
1,751.50
Daily Change
6.50 0.37%
Monthly
27.20%
Yearly
-5.83%
Q3 Forecast
1,726.10

Peers Price Chg Day Year Date
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Almirall 10.96 -0.16 -1.44% 27.89% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Amarin 15.33 0.30 2.00% 27.64% Sep/05
argenx SE 639.80 8.40 1.33% 31.21% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Fresenius Medical Care 41.99 0.28 0.67% 16.83% Sep/06
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Galapagos 28.44 1.84 6.92% 11.53% Sep/06
GN Store Nord 114.00 2.50 2.24% -30.85% Sep/05
GRIFOLS 12.30 0.02 0.16% 32.17% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Lonza 577.40 -0.80 -0.14% 7.68% Sep/05
Merck 109.55 1.05 0.97% -35.52% Sep/06
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
UCB 206.90 2.30 1.12% 28.99% Sep/05
Demant 248.80 8.80 3.67% -11.27% Sep/05

Indexes Price Day Year Date
EU600 549 -0.88 -0.16% 8.42% Sep/05

Genmab traded at 1,751.50 this Friday September 5th, increasing 6.50 or 0.37 percent since the previous trading session. Looking back, over the last four weeks, Genmab gained 27.20 percent. Over the last 12 months, its price fell by 5.83 percent. Looking ahead, we forecast Genmab to be priced at 1,726.10 by the end of this quarter and at 1,652.10 in one year, according to Trading Economics global macro models projections and analysts expectations.

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.